Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2024 | $48.00 | Buy | Stifel |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $37.00 | Overweight | Analyst |
| 11/13/2023 | $60.00 | Overweight | Morgan Stanley |
| 10/24/2023 | $50.00 | Overweight | Cantor Fitzgerald |
| 10/17/2023 | $62.00 | Outperform | Evercore ISI |
| 9/20/2023 | $70.00 | Mkt Outperform | JMP Securities |
| 9/1/2022 | $38.00 | Buy | Citigroup |
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San Diego, California. Enclosed below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the AASLD website. Full analyses will be available following their presentation within the Publications & Presentation section on Mirum's website. Presentations Abstract #5038: Volixibat for Cholestatic Pruritus in Prim
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD's The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed across all aspects of the
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,100 shares of common stock and 28,050 restricted stock units ("RSUs") to seven new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $42.00 per share, Mirum's closing trading price on November 8, 2024, and will vest over four years,
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi
Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00
H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously
Analyst resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation of LIVMARLI evaluated in the MARCH Phase 3 study.
- Form 13G
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price target.
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD's The Liver Meeting® 2024 PDUFA date for chenodiol in CTX is December 28, 2024 In-licensed global rights to PDE4D inhibitor MRM-3379 Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed across all aspects of the
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress. Conference call details: Tuesday, November 12, 2024 8:30 a.m. ET / 5:30 a.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 749358 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies LIVMARLI for treatment of PFIC granted marketing authorization in Europe Initiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions Conference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for second quarter 2024 and provided a business update. "The second quarter was marked by significant achievements across both our commercial medicines and development p
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)